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Abstract: Exogenous human follicle-stimulating hormone (hFSH), either derived from extraction 
and purification from the urine or obtained by recombinant technology in the form of follitropin α, 
β and δ (rFSH), has been used for decades in the treatment of infertility. The main applications of 
FSH treatment in the woman have been, and still are, ovulation induction in oligo-anovulatory 
subjects, and stimulation of the development of a cohort of follicles in patients undergoing 
controlled ovarian stimulation (COS) for in vitro fertilization (IVF). In the last years, two biosimilars 
of follitropin alfa, rFSH compounds structurally and functionally similar to the originator, have been 
approved and marketed for clinical use in Europe. Moreover, some other rFSH biosimilars are 
currently under investigation. The objective of this article is to review the available evidences 
comparing the efficacy, safety, and cost-effectiveness of rFSH follitropin alpha originator with its 
biosimilars, discussing the clinical trials that allowed biosimilars to get registration and marketing 
authorization.  
Keywords: recombinant human follicle-stimulating hormone (r-hFSH), r-hFSH biosimilars; 
controlled ovarian stimulation; in vitro fertilization 
 
1. Introduction 
Human follicle-stimulating hormone (hFSH) is produced by the anterior pituitary gland and 
plays a key role in the regulation of fertility in both men and women. Medications containing hFSH 
have been used for decades to treat infertile women with anovulatory cycles or to accomplish 
controlled ovarian stimulation (COS) in patients undergoing in vitro fertilization (IVF) [1]. Exogenous 
hFSH has also been used for the treatment of male hypogonadotrophic hypogonadism [2]. 
Since the early years of assisted reproductive technology (ART), exogenous hFSH has been 
administered to stimulate follicular growth both when mono-follicular development was desired 
(coupled to Intrauterine Insemination or timed intercourse) or when multi-follicular growth was 
required to obtain multiple oocytes, as in IVF [3]. Actually the number of retrieved eggs is a major 
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variable affecting IVF success rate [4], and therefore COS by FSH medications is considered to play a 
pivotal role in determining the effectiveness of IVF treatment [5].  
This review focuses on the different forms of recombinant FSH (rFSH) and on their biosimilar 
commercially available preparations, comparing their clinical efficacy, safety, and cost-effectiveness 
when used to treat women undergoing COS for IVF. Differently from other reviews on the topic, it 
provides not only a thorough update of the most recent studies published in peer-reviewed journals 
and of completed/ongoing clinical trials with FSH biosimilars in infertile women undergoing IVF, 
but also a detailed discussion of the design, results and power calculation of registration studies. This 
point is of prominent value to properly understand the difference with biosimilarity and 
bioequivalence when the most important IVF outcomes are concerned. 
Electronic searches were performed using Scopus and PubMed from January 2006 to May 2020 
selecting humans as species, classical article, review and medicine, biochemistry, genetics and 
molecular biology as subject area in Scopus, and humans as species, classical article, review, clinical 
trial—Phase I, II, III, IV—in PubMed. Abstracts, case reports, conference presentations were 
excluded. To identify all relevant published studies, we combined the following medical subject 
headings (MeSH) terms or keywords: “controlled ovarian stimulation” OR “in vitro fertilization” OR 
“anovulatory cycles” AND “human recombinant FSH” OR “follitropin-alpha“ OR “human FSH 
recombinant biosimilar”. All publications were in English and limited to human subjects, with the 
only exception of 18 additional papers concerning in vitro and in vivo animal model studies retrieved 
from the reference lists of some selected articles. Indeed the reference list of all retrieved articles was 
also reviewed and additional 10 articles were considered even if they were published before 2006. At 
least 50% of the references had to be articles published within the last 5 years, as requested by the 
editorial rules of Pharmaceuticals; for this reason, most studies comparing follitropin α vs. β and 
studies about corifollitropin α were excluded as they were published earlier. A total of 486 
publications were retrieved through the research databases. After excluding duplicated articles and 
publications that did not meet inclusion criteria, 63 articles remained, and were reviewed together 
with 11 research studies retrieved through the European Medicines Agency (EMA), the Therapeutic 
Good Administration (TGA) and the clinical trial.gov websites using the following keywords: FSH 
biosimilar, human and female infertility (Figure 1).  
 
Figure 1. Search strategy for identifying scientific publications and clinical studies for this 
comprehensive review paper. Abbreviations: EMA, European Medicines Agency, and TGA, 
Therapeutic Good Administration. 
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2. Structure of hFSH  
The human gonadotropins follicle-stimulating hormone (hFSH), luteinizing hormone (hLH) and 
chorionic gonadotropin (hCG) are complex heterodimeric glycoprotein hormones composed of two 
non-covalently linked protein subunits, the α- and β-chains.  
The α-subunit is identical in hFSH, hLH, and hCG, contains 92 amino acids and carries N-linked 
oligosaccharides added to the asparagine (Asn) residues 52 and 78. The β subunit is slightly different 
in the three gonadotropins, and confers the specificity of action. In hFSH, the β subunit is composed 
of 111 amino acids and it is responsible for proper folding, assembly, receptor binding specificity and 
biological properties. Notably, the hFSH-β subunit contains two glycosylation sites: Asn7 and Asn24. 
This entails four sites of glycosylation that confer different molecular weight to the hFSH: a fully 
glycosylated form of FSH, indicated as hFSH24 (Mr 24,000), the two di-glycosylated forms hFSH21 (Mr 
21,000) and hFSH18 (Mr 18,000), carrying glycosylations at the Asn7 and Asn24, respectively, and the 
hFSH15 (Mr 15,000), lacking glycosylation on the β-subunit [6]. Moreover, as each branch of the 
oligosaccharides may or may not terminate in a negatively charged sialic acid residue, different 
isoforms with different isoelectric points, plasma half-life (ranging from 3 to 4 h) and bioactivity may 
be generated [7]. Increased sialylation enhances hFSH metabolic stability, and thus lengthens its half-
life by decreasing both glomerular filtration and clearance by sialoglycoprotein receptors in the liver, 
which is the major site for gonadotropin clearance [3,8,9].  
The profile of hFSH isoform distribution is significantly dependent on its source, on the gender, 
on age and, in women, on the phase of the ovarian cycle [10]. The ratio of hFSH21/hFSH24 in the 
pituitary changes from hFSH21-dominance in women aged 21–24 to a roughly balanced proportion 
between 39 and 41 years, to hFSH24-dominance in women aged 55–81 [11]. Moreover, the composition 
of serum hFSH isoforms exhibits characteristic fluctuations during the menstrual cycle; in the early 
follicular phase acidic isoforms predominate, gradually shifting towards preferentially less acidic 
isoforms during the mid-follicular and late follicular phases, as ovulation approaches [9,10]. The less-
acidic isoforms exhibit a shorter serum half-life as they have a faster clearance than the acidic 
isoforms. During the follicular recruitment, taking place in the early follicular phase, a longer half-
life of hFSH ensures a higher efficacy in recruiting the pool of small antral follicles that will grow that 
month. Differently, during the more advanced phase of follicular development, when a dominant 
follicle has already been selected, isoforms with a shorter half-life are preferable to ensure the final 
maturation of granulosa cells and their optimal support to the cytoplasmic maturation of the oocyte 
[3].  
The hypoglycosylated hFSH is much more biologically active than fully glycosylated hFSH [12], 
and highly acidic hFSH isoforms are produced in higher concentration after the menopause than 
during the reproductive age. This suggests that glycoform composition of circulating hormones is 
dynamic and has a physiological role [13], thus modulating the hormone-receptor structural 
interaction and the downstream signaling [14]. Indeed, it is reported that pituitary hFSH21/18 exhibits 
a 9- to 20-fold higher hFSH receptor-binding activity and occupies twice as many receptors than 
hFSH24 [11].  
3. hFSH as a Medication: Historical Background  
In the history of human infertility therapy, the availability of drugs inducing ovulation in oligo-
anovulatory patients or promoting the synchronous growth of a cohort of follicles in order to obtain 
several oocytes to be in vitro fertilized represented an enormous progress. The use of gonadotropins 
for the treatment of infertility began in the 1930s, following the discovery of FSH and LH. Early 
preparations were obtained from animal sources—e.g., the pregnant mare serum—or from extracts 
of the human pituitary gland taken post-mortem [15].  
Subsequently, the human menopausal gonadotropin (hMG), extracted from the urine of women 
in menopausal age and containing a mixture of 1:1 FSH:LH activity together with miscellaneous 
urinary proteins, proved to be effective for ovarian stimulation and generally well tolerated [16]. The 
use of urinary gonadotropins was extended to women undergoing IVF treatment in the early 1980s, 
and the development of medications containing human gonadotropins continued, with the objective 
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of improving their purity and providing a product with pure hFSH, free of hLH and other urine-
derived contaminants. Indeed, different products of urinary derivation became available, such as 
urofollitropin (u-hFSH) in 1983, which had a FSH purity of approximately 5%, and highly purified 
urofollitropin (HP-u-hFSH) in 1993, with an FSH purity of approximately 95%. In more recent years, 
another urine-derived pharmaceutical gonadotropin, the highly purified HMG (HP-hMG), with a 
total gonadotropin content of approximately 70%, was developed [3]. In the early 1990s recombinant 
human FSH (r-hFSH) was obtained, and was widely recognized as a further progress in hFSH 
pharmacology, having higher purity, more intense specific activity, and superior efficacy in terms of 
pregnancy rate in in vitro fertilization cycles when compared with u-hFSH [17]. Urinary hFSH and 
hMG preparations, being extracted from post-menopausal urine, contain mostly hFSH24 [6]. 
Lombardi et al. showed a predominance of highly sialylated, highly branched glycans in u-hFSH as 
compared to r-hFSH, implying a weaker effect of u-hFSH on steroidogenesis in rodent cell lines; this 
observation suggests that differences in purity and molecular structure of medications are likely to 
be reflected in different biological properties that relevantly affect clinical results [10].  
The composition of the recombinant hormone depends on manufacturing technology; briefly, 
the preparation of r-hFSH was obtained as follows: genes coding for α- and β-subunits of hFSH were 
transfected through plasmid expression into mammalian cells, the Chinese hamster ovary (CHO) 
cells [7], which are able to perform the post-translational step of hormonal production, protein 
folding and glycosylation [18]. Next, crude CHO cell culture supernatants were processed by using 
five chromatographic purification steps and ultrafiltration. The complete amino acid sequence of the 
α- and β-subunits of r-hFSH were determined by automated sequencing, while the structure of the 
carbohydrate chains was identified by glycan mapping.  
In the early 2000s the manufacturing process of r-hFSH was further improved in order to 
increase the specific activity and ensure a consistent isoform profile. The calibration of the final 
product was accomplished through a new method, the filled-by-mass process, that offers the 
opportunity to ensure improved batch-to-batch consistency, to guarantee that the r-hFSH dose is 
independent from any variation associated with the bioassay, and hence to standardize the ovarian 
stimulation and response [19]. Indeed, the consistency of the ovarian response to r-hFSH is a key 
issue; for clinicians performing IVF, the very low variability in the r-hFSH content between batches 
is a major advantage as it allows to finely tuning r-hFSH stimulation. The potential benefits of an 
optimal, individualized r-hFSH dose are the increased effectiveness and safety of COS, as well as the 
minimization of the risk of cycle cancellation for hypo- or of hyper-response [19]. 
4. Recombinant Human FSH (r-hFSH)  
Currently, there are different r-hFSH products on the market: (a) follitropin α (Gonal-F®, Merck 
KgaA, Darmstadt, Germany), available in Europe since 1995 and in USA from 2004 [20], (b) follitropin 
β (Puregon®, MSD, Darmstadt, Germany), marketed in Europe from 1996 [21] and in USA from 2004 
(Follistim AQ, Merck KgaA, Darmstadt, Germany) [22], and (c) follitropin δ (Rekovelle®, also named 
FE 999049, Ferring Pharmaceuticals, St. Prex, Switzerland), recently developed and produced using 
human fetal retinal cells [23,24]. Follitropin α, β and δ have the same amino acid sequence; 
nevertheless, they differ in glycosylation, composition of sialic acid residues and isoelectric 
coefficients: follitropin α is more acidic than follitropin β, resulting in slightly different biological 
activity, half-life and metabolic clearance. Follitropin α and β have only α2,3-linked sialic acid, as 2,6-
linked sialic acid is absent in CHO-derived r-hFSH; differently, follitropin δ includes tri- and tetra-
sialylated glycans, has α2,3- and α2,6-linked sialic acid content, different sugars (such as N-
acetylgalactosamine), and carries additional linkages among carbohydrates (such as bisecting N-
acetylglucosamine and antennary fucose) [25,26].  
Preclinical data from animal models showed that the currently available r-hFSH medications 
have no teratogenic, mutagenic or clastogenic effects, an evidence that was further supported by a 
series of trials and meta-analysis regarding the safety and effectiveness of r-hFSH for women 
undergoing IVF [16,27–29], including poor responder patients of advanced age and women with 
polycystic ovary syndrome (PCOS) [30]. Pharmacokinetic studies showed that r-hFSH is no more 
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detectable in the woman’s blood by the time of embryo implantation, and no detrimental effects on 
the fetus after accidental exposure to r-hFSH in early pregnancy have been reported; moreover, r-
hFSH is not believed to increase the risk of abortion or affect birthweight [31]. 
Follitropin δ received its marketing license in Europe in 2016 [32] and in Australia in 2017 [33]; 
nonetheless, it remains under additional clinical monitoring. In vitro, follitropin δ was observed to 
be equivalent to follitropin α when tested in cell-free FSH-receptor binding assays performed in 
stably transfected with the human FSH receptor human embryonic kidney cells and in human 
granulosa cells [26]. However, in rat models, follitropin δ was shown to have different 
pharmacokinetic and pharmacodynamic profiles, a quicker clearance, and a lower apparent potency. 
Consequently, follitropin δ cannot be dosed according to bioactivity or specific bioactivity in 
biological assays, as other follitropins are, and it is instead dosed by mass [26].  
In order to overcome the relatively short biological half-life of r-hFSH, which requires daily 
administration, a long-acting form of r-hFSH, corifollitropin α (CFα, also named Elonva®; MSD, 
Readington, NJ, USA), was produced in transfected CHO cells [34]. This chimeric molecule includes 
the sequence encoding the C-terminal extension of hCG beta subunit (hCG-β), bearing four O-linked 
glycosylation sites and providing extended half-life of approximately 65 h [35], added to the FSH β-
subunit. As a result of the longer serum half-life, a single injection of CFα can replace daily FSH 
injections for the first 7 days of COS, sustaining multiple follicular development as required for IVF. 
In primary cultures of human granulosa cells, CFα was demonstrated to maintain the specific actions 
of follitropin alpha, being even more potent in increasing aromatase gene expression inducing 
estrogen synthesis [36].  
Another rFSH is under testing and is not yet marketed; it is called follitropin ε (FSH-GEX; 
Glycotope, Berlin, Germany) and is produced using a human blood cell line derived from myeloid 
leukemia cells [37]. Follitropin ε shows a high content of bisecting N-acetlyglucosamine, a high 
antennarity and a high degree of sialylation, in particular after enrichment of the acidic isoforms. 
Differently from follitropins α and β, follitropin ε is highly fucosylated and has a ratio of 2,3 to 2,6 
sialylation of about 1:1, whereas follitropin α and β do not have any bisecting N-acetylgalactosamines 
or 2,6 sialylation [34]. In phase I studies, follitropin ε and follitropin α had similar pharmacokinetics, 
whereas pharmacodynamic activity (measured considering follicle growth and serum inhibin B 
secretion by granulosa cells) was higher with follitropin ε than with follitropin α [37,38]. 
From a clinical point of view, follitropin α and β were repeatedly shown to be equally effective 
for the use in COS for IVF. Actually, for about 25 years, they have been the only r-hFSH preparations 
available for clinical use, and besides comparative studies, a huge amount of real life data showed 
their substantial equivalence in inducing multiple follicular growth, oocyte yield, and live birth rate 
after IVF [39,40]. 
Follitropin δ was introduced on the market much more recently; its efficacy was compared to 
follitropin α in the phase III study ESTHER-1, including 1326 women submitted to COS using either 
a starting dose of follitropin δ based on body weight and anti-Müllerian hormone (AMH) or a daily 
dose of 150–450 IU of follitropin α [41,42]. The non-inferiority of follitropin δ to follitropin α for the 
primary endpoints (ongoing pregnancy rate: 30.7% and 31.6%, respectively, and ongoing 
implantation rate: 35.2% and 35.8%, respectively) was demonstrated. Also the live birth rate was 
similar between follitropin α and follitropin δ (29.8% and 30.7%, respectively), and fewer women in 
the follitropin δ study arm required preventive measures against ovarian hyperstimulation syndrome 
(OHSS) [41]. The European Medicines Agency (EMA) assessment report stated that in the ESTHER-
1 trial, the non-inferiority of follitropin δ vs. follitropin α was affected by the heterogeneity of 
response in different age groups. Indeed, Lunenfeld et al. reported that the non-inferiority was 
applied to the 15% of the study population aged ≥38 years, whereas it was not demonstrated for 
women aged ≤37 [34]. Finally, it was also noted that there was a higher number of cancelled cycles 
due to poor response in the follitropin δ arm [41]. The risk/benefit balance of follitropin δ was 
considered positive, as the most frequent adverse reactions reported were headache, pelvic 
discomfort, nausea, and fatigue [23]. Follitropin δ demonstrated higher bioavailable dose and lower 
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serum clearance compared with follitropin alfa [25]. Based on these differences, it was concluded that 
follitropin δ and α are not easily interchangeable in clinical practice. 
After a secondary analysis of ESTHER-1, Fernández-Sánchez et al. confirmed that individualized 
dosing with follitropin δ significantly reduced moderate/severe OHSS and/or the need of OHSS 
preventive interventions in patients undergoing up to three COS cycles, and the greatest benefit was 
observed in patients in the highest AMH quartile, those with the maximal risk of severe OHSS [43]. 
Another study, the controlled, assessor-blind ESTHER-2 showed that in women undergoing 
repeated COS cycles (cycles 2 and 3) following initial stimulation with follitropin δ or α (cycle 1), the 
incidence of treatment-induced anti-hFSH antibodies with follitropin δ was 0.8% and 1.1% in cycles 
2 and 3, respectively, which was similar to the incidence in cycle 1 (1.1%) [44]. Treatment with either 
follitropin δ or α obtained similar mean number of retrieved oocytes (9.2 versus 8.6 (cycle 2); 8.3 
versus 8.9 (cycle 3)), ongoing pregnancy rate (27.8% versus 25.7%; 27.4% versus 28.0%) and live birth 
rate (27.4% versus 25.3%; 26.3% versus 26.9%). Notably, women with pre-existing anti-hFSH 
antibodies were safely treated with follitropin δ without boosting an immune response or affecting 
the ovarian response, suggesting a lack of immunogenicity of follitropin δ in patients undergoing 
repeated ovarian stimulation cycles, similarly to follitropin α and follitropin β that had not shown 
any anti-hFSH antibody production [45].  
In comparative clinical trials, CFα was shown to be an effective alternative to daily injections of 
r-hFSH in COS [46]. Comparable results in terms of ongoing pregnancy rate, miscarriage rate, and 
live birth rate were reported with the use of CFα versus daily r-hFSH [47]. However, an increased 
risk of OHSS in patients defined as high responders (e.g., young women with polycystic ovary) was 
also reported [47], limiting the use of CFα to specific cohorts of IVF patients, those with an expected 
normal or poor ovarian responsiveness to r-hFSH.  
To date, no phase III studies have been registered in available clinical trial repositories for 
follitropin ε. 
5. Biosimilar r-hFSH (Follitropin α) 
The term “biosimilar” describes an off-patent copy of a therapeutic substance [48]. The US Food 
and Drug Administration (FDA) characterizes biosimilars as biologic products that are highly similar 
to the reference product (originator), notwithstanding minor differences in clinically inactive 
components, and that have no clinically relevant differences in comparison with the reference 
product in terms of safety and efficacy [49]. This definition describes a product that is similar, but not 
identical to the originator. Indeed biosimilars may still differ from the originator in biological 
potency, purity, composition of isoforms and/or various glycosylation profiles [50], with consequent 
differences in the clinical efficacy and/or safety [51,52]. This “non-identity” represents the main 
difference from generic drugs, which are small synthetic molecules chemically identical and fully 
bioequivalent to the brand listed medication, identical both in pharmacokinetic and 
pharmacodynamic characteristics [53].  
As biosimilarity is a concept alluding to the evidence-based high-standard comparability, 
studies are needed to demonstrate the equivalence of a biosimilar to the originator. Differently from 
chemically-synthesized medications, biotechnology-derived products are subject to an inherent 
molecular variability, even if minor batch-to-batch physicochemical variations may be 
therapeutically acceptable [48]. 
The patent of follitropin α expired in 2012 in many European countries [54], and it became 
possible to produce a biosimilar follitropin α. To date, two follitropin α biosimilars, Ovaleap® 
(Theramex Ireland Limited, Dublin, Irland) and Bemfola® (Afolia®, Finox Biotec AG, Balzers, 
Liechtenstein) have been authorized by the EMA. The first is produced by a CHO-derived cell line 
after adaptation to serum free conditions [55], whereas the second is produced by a pre-adapted 
dihydrofolate reductase deficient CHO host cell line [56]. Both follitropin α biosimilars are 
administered via the same route, at the same dose, and for the same indications [53]. Their production 
is strictly regulated by EMA guidelines, and their use has been approved in the USA since 2016 [57].  
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Moreover, some other r-hFSH biosimilars have been marketed only in their countries of origin, 
such as Primapur® (IVFarma LLC, Moscow, Russia), DA-3801® (Dong-A ST/Genexine, Seoul, South 
Korea), Folitime® (also named GEMA, Amega Biotech S.A., Buenos Aires, Argentina), LM-001® (also 
named Alphamab, Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Andhra Pradesh, India), 
Gonapure® (Minapharm Pharmaceuticals, Cairo, Egypt) and Cinnal-F® (CinnaGen, Tehran, Iran and 
Singapore Biotech, Singapore). 
Winstel et al. compared the originator Gonal-F® to the biosimilar Ovaleap® for the molecular 
mass, primary and secondary structure, in vitro biological activity, long-term stability at room 
temperature and product-related impurities, demostrating that biosimilar and originator have similar 
characteristics derived from the manufacturing process [55]. Moreover, increasing concentrations of 
the originator or of its biosimilars were used for inducing primary granulosa luteinization and hFSH 
receptor-transfected human embryonic kidney (HEK293) cellular responses [13]. Ricetti et al., 
comparing the originator to the biosimilars, demonstrated that they induced similar intracellular 
responses and steroidogenesis in HEK293 cells, reflecting similar bioactivity, and overall structural 
homogeneity. Slight differences in glycosylation profiles characteristic of the follitropin α were 
detected and are likely due to the specific enzymatic equipment of the source cell lines [13].  
Regarding the molecular mechanisms underlying hFSH activity on steroidogenesis, 
proliferation and survival/apoptosis, several studies focused on the Gs/cAMP/PKA pathway 
activated by hFSH after binding to its receptor [58]. Follitropin α originator and biosimilars revealed 
comparable in vitro hormone-induced intracellular signalling and effect on steroidogenesis, resulting 
in similar dose-response curves for both the 3′,5′-cyclic adenosine monophosphate (cAMP) synthesis, 
enhanced through the response element binding protein (CREB) and extracellular-regulated kinase 
1/2 (ERK1/2) phosphorylation [59], and the intracellular Ca2+ increase [60].  
6. Clinical Trials Comparing Follitropin α Biosimilars vs. Originator  
After manufacturing of the biosimilar product a phase III Randomised Clinical Trial (RCT) is 
required to demonstrate that structural changes do not adversely affect the identity, purity, or 
potency of the potentially approved biologic product [61]. 
The first follitropin alpha biosimilar approved for clinical use in Europe was Ovaleap®, that was 
approved by EMA in 2013 [62] basing on the clinical trial NCT02809989 (Table 1). To establish the 
efficacy of Ovaleap® compared to the follitropin α originator Gonal-F®, EMA requested a single 
prospective randomized trial in which the primary endpoint was the number of retrieved oocytes; as 
for the safety, the incidence of OHSS was the main considered indicator [61]. Equivalence was 
considered as demonstrated if the two-sided 0.95 confidence interval for the difference in the number 
of retrieved oocytes would have fallen within the range of ± 3 oocytes. The phase III study was 
performed by Strowitzki et al., who studied a selected population of women undergoing COS for IVF 
and found that Ovaleap® was equivalent to Gonal-F® in terms of retrieved oocytes [63]. This 
multinational, multicenter, randomized (1:1), active-controlled, assessor-blind, comparative study 
included infertile women aged 18-37, with a body mass index between 18 and 29 kg/m2 and regular 
menstrual cycles of 21 to 35 days. During the initial 5-day fixed-dose phase, 153 women received 150 
IU/day of Ovaleap®, and 146 received the same dose of Gonal-F®; a 10–15-days dose-adaptation phase 
followed, during which the administered dose could be adjusted every 3–5 days, up to a maximum 
of 450 IU/day. Using an imputation value of zero for patients without oocyte retrieval, Ovaleap®-
treated patients obtained 12.2 ± 6.8 retrieved oocytes vs. 11.9 ± 6.9 for Gonal-F®–treated patients. 
Without applying any imputation, oocyte retrieval was nearly identical in either arms (12.2 ± 6.7 vs. 
12.1 ± 6.7 with Ovaleap® and Gonal-F®, respectively). In the same study, several secondary endpoints 
were considered: the follicle number, size, and the endometrial thickness resulted to be comparable 
between groups; approximately 90% of the started clinical pregnancies ended with a live birth, 89.1% 
(41/46) in the Ovaleap® group and 88.7% (47/53) in the Gonal-F® group. The take-home baby rates, 
defined as the percentage of randomized patients whose treatment cycle ended with a live birth, were 
comparable: 26.8% (41/153) with Ovaleap® and 32.2% (47/146) with Gonal-F®, respectively. Among 
undesired effects, the OHSS rate was 4.6% (7/153) in the Ovaleap® group and 2.7% (4/146) in the 
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Gonal-F® group, abdominal pain was observed in 3.3% of patients (5/153) treated with Ovaleap® and 
0.7% (1/146) of those treated with Gonal-F® [63]. Finally, Strowitzki et al. concluded that Ovaleap® 
had shown the same efficacy and safety as Gonal-F® for ovarian stimulation of infertile women below 
37 years undergoing IVF.  
The second European biosimilar follitropin α, Bemfola® (Afolia®), was approved by EMA in 2014 
[56]. Preliminarly, in a phase I, randomized, open-label, crossover trial (NCT02459418), Wolzt et al. 
showed in 32 healthy young women that Bemfola® exhibited clinical pharmacokinetic and safety 
profiles comparable to Gonal-F® [64]. The clinical trial for its approval on market was a randomized, 
multicentre, phase III study (NCT01121666) (Table 1) including 372 women undergoing IVF, in which 
the efficacy and safety of Bemfola® was compared to that of the originator Gonal-F® [65]. A selected 
population of women aged 20–38 were randomized 2:1 to receive a single, daily, subcutaneous 150 
IU dose of either Bemfola® or Gonal-F®. The study primary endpoint was the number of retrieved 
oocytes; equivalence was considered as demonstrated if a difference lower than ± 2.9 oocytes would 
have been observed. Bemfola® and Gonal-F® treatments resulted in a comparable number of retrieved 
oocytes (10.8 ± 5.11 vs. 10.6 ± 6.06, respectively); among the secondary endpoints, a similar clinical 
pregnancy rate per embryo transfer in the first and second treatment cycles was observed (Bemfola®: 
40.2% and 38.5%, respectively; Gonal-F®: 48.2% and 27.8%, respectively). The incidence of OHSS was 
5.6% in the Bemfola® group and 3.3% in the Gonal-F® group. Thus, Rettenbacher et al. [65] concluded 
that Bemfola® and Gonal-F® had similar clinical efficacy and safety profiles.  
Unfortunately, these two clinical trials appear to have some major weak points: (1) they were 
both performed on a selected population of young women undergoing IVF, with an expected optimal 
responsiveness to r-hFSH, and (2) their power calculation was performed choosing the number of 
retrieved oocytes as the primary endpoint, and leaving other clinically pivotal variables (e.g., ongoing 
pregnancy rate, live birth rate) as secondary endpoints [61]. Indeed, the average population of women 
undergoing IVF in the daily routine clinical practice includes a relevant proportion of subjects older 
than 37, with an expected reduced responsiveness to COS and needing a starting dose much higher 
than 150 IU/day, which was the dose used in registration trials. Moreover, in the real-life clinical 
practice several women undergoing IVF have PCOS, with irregular, anovulatory cycles, 
hyperandrogenism, and a clear tendency at overresponding to FSH, developing a huge number of 
middle-size growing follicles and having a risk of OHSS much higher than average. A clinical study 
aimed at assessing whether a medication is suitable for COS should include a wide population 
mirroring the one that is usually encountered in the daily work, and not a selected, ideal population 
of subjects with better-than-average prognosis and lower-than-average risk.  
It is quite common that studies dealing with medications used in COS adopt the number of 
retrieved oocytes as the primary endpoint representing a sensitive endpoint for an accurate 
comparison between such medications [53], as it avoids differences that may not be attributable to 
the product. Indeed ongoing pregnancy rate or live birth rate could be linked to confounding factors 
unrelated to medications, and should be rather used as a secondary efficacy measure [53]. However, 
this view is questionable for at least two reasons.  
First, there is no doubt that the effectiveness of IVF is witnessed by live births, and that live birth 
rate is the only endpoint fully expressing the efficacy of any infertility treatment. When two 
procedures (e.g., two different incubators for human embryos) are compared in an RCT, the only 
acceptable primary endpoint is live birth rate, and no surrogate endpoints (e.g., the proportion of 
embryos surviving the culture) are accepted to establish equivalence. The reason why in some clinical 
RCTs dealing with medications the primary endpoint is the number of retrieved oocytes is only 
economical: this choice allows to include in the study a rather low number of patients (as all women 
produce several oocytes), whereas choosing the live birth as primary endpoint would compel to 
include many more observations (only about 30% of women will have a live birth), increasing 
relevantly the cost of the trial. 
Second, when a study is powered according to a given primary endpoint, comparing the 
secondary endpoints must be considered just an occasional observation; drawing conclusions after 
comparing the secondary endpoints is meaningless and incorrect, as the number of observations is 
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insufficient to get a meaningful comparison. In other words, if a study comparing two drugs is 
powered to detect a difference in the number of retrieved oocytes, no meaningful comparison can be 
made for the number of pregnancies, live births, or for the incidence of OHSS: these are just occasional 
observations that should be verified in further, adequately powered studies. 
Analyzing the two registration trials, other points were also noticed. The increased rate of OHSS 
observed with Bemfola [66] could be due to a more variable and abrupt oestradiol rise, in turn linked 
to a higher batch-to-batch variability and to differences in glycosylation profiles [66]. Indeed, even if 
Bemfola® and Ovaleap® are similar to the reference product Gonal-F®, their structures are analytically 
not identical due to post-translational modifications that result from differences in the production 
and purification systems [34]. Specifically, differences in glycosylation were observed between the 
biosimilars and Gonal-F®, with Bemfola® showing higher antennarity, higher sialylation and higher 
batch-to-batch variability in activity compared to Gonal-F® [66], whereas Ovaleap was shown to have 
a higher amount of the sialic acid N-glycolyl neuraminic acid compared with Gonal-F® [53]. These 
differences were considered by EMA as minor and acceptable, even if they could result in more 
pronounced variability in hFSH receptor activation [66]. These findings could be of clinical 
importance especially in “non-ideal” patients, like older women poorly responding to r-hFSH, or, on 
the other side, young women with PCOS and subsequent “constitutional” hyper-responsiveness to 
COS [61]. 
In another clinical trial, the efficacy of Bemfola® was compared with that of a HP-uhFSH 
(Fostipur®, IBSA, Farmaceutici Italia Srl, Lugano, Switzerland). Requena et al. performed a phase IV 
randomized, parallel-group, trial (NCT02503605) including 130 oocyte donors aged 18–35 years, with 
BMI 18- 30 kg/m2 and antral follicle count (AFC) >20, suggesting an optimal ovarian responsiveness 
to COS. The number of retrieved, mature oocytes was considered the primary outcome whereas days 
of stimulation, total FSH dose, estradiol and progesterone concentration at ovulation trigger, 
fertilization rate, number of cryopreserved embryos, implantation rate, cancellation rate and patient 
compliance were all considered as secondary outcomes. The study was started in 2016, but no 
preliminary data are available yet [67]; of note, this study has the same conceptual limitations of the 
previous ones, which are the choice of a selected, optimal population, and a power calculation based 
on a primary endpoint that does not fully express IVF efficacy. 
Other observational, phase III and IV studies on Bemfola® that are still ongoing or have been 
completed but have not yet published the results, are shown in Table 1. 
Recently, after the NCT03857230 (Table 1) phase I interventional trial demonstrating the safety 
of the follitropin α biosimilar Primapur®, a multicenter, randomized (1:1), embryologist-blinded, 
parallel-group, comparative phase III study (NCT03088137) was performed (Table 1) [68]. It enrolled 
good prognosis women aged 20–35 years with tubal and/or male infertility, who underwent COS 
using a gonadotropin-releasing hormone antagonist (GnRH-ant) protocol. Over the initial 5-day 
fixed-dose regimen, patients received 150 IU/day of Primapur® (n = 55) or Gonal-F® (n = 55), followed 
by dose adaptation. Again, the primary endpoint for assessing the therapeutic equivalence was the 
number of retrieved oocytes, using a pre-determined clinical equivalence margin of ±3.4 oocytes. A 
similar number of oocytes was retrieved in both groups (12.16 ± 7.28 in the Primapur® group and 
11.62 ± 6.29 in the Gonal-F® group). Additionally, no statistically significant differences were found 
for secondary endpoints: clinical pregnancy rate (26.5% vs. 32.7%, respectively), and take-home baby 
rate (28.6% and 26.5%, respectively). OHSS was observed in 7.27% and 3.64% of patients in the 
biosimilar and originator groups, respectively. 
The safety and efficacy of the follitropin alpha biosimilar DA-3801 was investigated by Moon et 
al. [69] in a phase III, multicenter, randomized, non-inferiority trial (NCT01820728) comprising 97 
women randomized to receive COS using DA-3801 (n = 49) or Gonal-F® (n = 48) (Table 1). The number 
of retrieved oocytes was set as primary endpoint, whereas the total FSH dose, the length of 
stimulation, the serum estradiol levels on the day of oocyte maturation trigger, and the fertilization, 
implantation and pregnancy rates were considered as secondary endpoints. The number of retrieved 
oocytes was 13.0 ± 6.2 versus 10.6 ± 6.7 for DA-3801 and Gonal-F®, respectively, in the intention-to-
treat (ITT) population, and 12.7 ± 6.4 versus 11.0 ± 7.1 for DA-3801 and Gonal-F®, respectively, in the 
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per-protocol (PP) population. The non-inferiority of DA-3801 was assessed with differences of 2.3 ± 
6.5 and 1.7 ± 6.7, in the ITT and PP populations, respectively. The total dose of FSH (1789.8 ± 465.5 
versus 2055.6 ± 646.7 pg/mL) and the length of stimulation (8.3 ± 1.4 versus 9.1 ± 1.9 days) in the ITT 
population were significantly lower in the DA-3801 group. Pregnancy and implantation rates, as well 
as the incidence of OHSS, were comparable in the two groups. The previously reported criticism on 
the study methodology applies also in these two studies. Other clinical trials for other biosimilars of 
follitropin α (Folitime®, LM-001® and GONAPUR®) have recently been concluded, but the results are 
not yet available (Table 1). 
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Table 1. Clinical trials available in the literature and in the U.S. National Library of Medicine|U.S. National Institutes of Health|U.S. Department of Health & 
Human Services (available online at: https://clinicaltrials.gov/ct2/home) considering follicle-stimulating hormone (FSH) biosimilar administration to women for 
infertility treatment. 




A study to 
evaluate the effect 
of Ovaleap® on the 
pregnancy rate 
and clinical effects 
as well as the user-









Study Type: Observational  
Observational model: Single 
group prospective treatment 
cohort 
Enrolment: 507 participants 
(18–40 years) 
Drug: Ovaleap®  
• Number of retrieved oocytes 
(primary) 
• Clinical pregnancy rate (primary) 
• Days of stimulation 
• Total Ovaleap® dose administered 
• Estradiol at the ovulation trigger 
• Endometrial thickness at the 
ovulation trigger  
• Type of ovulation trigger (β-hCG, 
GnRH agonist) 
• Number of metaphase II (MII) 
oocytes  
• Number of fertilised oocytes 
• Day of embryo transfer and 
number of transferred embryos 




of AFOLIA and 
US 
Gonal-F® RFF redi-










Study Type: Interventional 




Masking: None (Open Label) 
Enrolment: 42 participants 
(18-42 years) 
Drugs: Afolia, Gonal-F® 
• Baseline corrected FSH area under 
the serum concentration-time curve 
from zero to the last quantifiable 
measurement (AUC (0-last)) 
(primary) 
• Baseline corrected FSH maximum 
serum concentration (Cmax) 
(primary) 
• Baseline corrected FSH area under 
the serum concentration-time curve 
extrapolated to infinity (AUC (0–∞)) 
• Baseline corrected time to reach 
maximum FSH serum concentration 
(Tmax) 
• Baseline corrected FSH apparent 
terminal half-life 
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Table 1. Cont. 
      
• Baseline corrected 17ß-estrodiol 
(E2) serum exposure AUC (0-last) 
• Baseline corrected E2 Cmax 
• Baseline corrected E2 Tmax 
FOLIA® NCT01687712 
Phase III study 
comparing efficacy 
and safety of 
AFOLIA vs. 
Gonal-F® RFF in 







not published yet 
Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 





Enrolment: 1100 participants 
(35–42 years) 
Drugs: Afolia, Gonal- F® 
• Clinical pregnancy rate after one 
cycle of treatment - ITT population 
(primary) 
• Clinical pregnancy rate after one 
cycle of treatment - PP Population 
(primary) 
• Days of stimulation-cycle 1 
• Total r-hFSH dose administered - 
cycle 1 
• Daily r- hFSH dose-cycle 1 
• Number of retrieved oocytes-cycle 
1 
• Local and systemic adverse 
events: dermal response to 
injection-cycle 1 
• Local and systemic adverse 
events: dermal response to injection 
by severity-cycle 1 
• Overall summary of adverse 
events (AEs)-cycle 1 
• Adverse events of special interest:  












Study Type: Interventional 




Masking: None (Open Label) 
Enrolment: 32 participants 
(18–38 years) 
Drugs: Afolia, Gonal-F® 
• Area under the serum 
concentration curve (AUC) of FSH 
(primary) 
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efficacy and safety 











Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 
Intervention model: Parallel 
Assignment  
Masking: Single (Outcomes 
Assessor) 
Enrolment: 460 participants 
(20–38 years) 
Drugs: Afolia, Gonal- F® 
• Number of retrieved oocytes (per 
protocol population) (primary) 
• Number of retrieved oocytes 
(intention-to-treat population) 
(primary) 
• Number and size of follicles ≥12 
mm on day 8 of stimulation 
• E2 concentration on day 8 and the 
day of ovulation trigger 
• Total r-hFSH dose administered 
• Oocyte quality 
• Fertilisation rate 
• Embryo quality: mean number of 
blastomeres 
• Number of participants with 
cryopreserved 2PNs, 
embryos/blastocysts 
• Days of stimulation 
• and 9 more 
BEMFOLA® NCT02942849 
Post-authorisation 











Study Type: Observational  
Observational model: cohort, 
prospective 
Enrolment: 1195 participants 
(≥18 years) 
Drug: Bemfola® 
• Number of retrieved oocytes 
[primary] 
• Antral follicle count (AFC) 
• Basal FSH level 
• r-hFSH dose on first and last day 
of stimulation 
• Days of stimulation 
• Total r-hFSH dose administered 
• Type of ovulation trigger (ß-hCG, 
GnRH agonist  
• Number of fertilised oocytes  
• Number of cryopreserved 2PN 
embryos 
• Number of transferred embryos  
• and 5 more 
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Table 1. Cont. 
BEMFOLA® NCT03767218 













Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 
Intervention model: Two-arm 
design with 1:1  
Masking: None (Open Label) 
Enrolment: 40 participants 
(18–36 years) 
Drug: Bemfola® 
• Number of COC (cumulus-
oocyte-complex) [primary] 
• Endocrine profile 
• Total r-hFSH dose administered 
• Days of stimulation 
• Days of GnRH antagonist 

















Study Type: Observational  





• Number of retrieved oocytes 
[primary] 
• Number of fertilised oocytes 
• Embryo quality 
• Number and quality of 
transferred embryos 
• Fertilisation and implantation rate 














Study Type: Interventional 
Phase: Phase IV 
Allocation: Randomized 
Intervention model: Parallel 
Assignment 
Masking: None (Open Label) 
Enrolment: 130 participants 
(18–35 years) 
Drugs: Bemfola®, urinary FSH 
• Number of metaphase II (MII) 
oocytes [primary] 
• Days of stimulation 
• Total FSH dose administered 
• Estradiol at the ovulation trigger 
• Progesterone at the ovulation 
trigger 
• Fertilisation rate 
• Percentage of cryopreserved 
embryos 
• Implantation rate 
• Cancellation rate 
• Degree of satisfaction (numbers 0-
10) 
• Apoptosis rate in granulosa cells 
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Table 1. Cont. 
BEMFOLA® NCT02625519 
Efficacy of urinary 
vs. recombinant 
FSH in oocyte 











Study Type: Interventional 
Phase: Phase IV 
Allocation: Randomized 
Intervention model: Parallel 
Assignment 
Masking: None (Open Label) 
Enrolment: 180 participants 
(18-30 years) 
Drugs: Bemfola®, urinary 
hFSH, 
 
• Number of COC (cumulus-
oocyte-complex) obtained [primary] 
• Number of COC (cumulus-
oocyte-complex) obtained/puncture 
[primary] 
• Number of metaphase II (MII) 
oocytes  
• Number of 
inseminated/microinjected oocytes 
• Days of stimulation 
• FSH treatment units obtained by 
oocyte 
• FSH treatment cost per oocyte 
obtained 
• Fertilisation rate 
• Occurrence of side effects 
FOSTIPUR® NCT02785822 















Study Type: Interventional 
Phase: Phase IV 
Allocation: Randomized 
Intervention model: Parallel 
assignment 
Masking: Single (Investigator) 
Enrolment: 19 participants 
(18–38 years) 
Drugs: Fostipur®, hMG-HP 
• Number of metaphase II (MII) 




The safety and 
pharmacokinetics 









Study Type: Interventional 




Masking: None (Open Label) 
Enrolment: 28 participants 
(18–40 years) 
Drugs: Primapur®, Gonal- F® 
• Area under the serum 
concentration of FSH - Time Curve 
(AUC (0-192)) [primary] 
• Maximum serum concentration of 
FSH (Cmax) [primary] 
• Time to reach a maximum FSH 
serum concentration (Tmax) 
• FSH apparent terminal half-life 
(T1/2) 
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Table 1. Cont. 
PRIMAPUR® NCT03088137 
Study to compare efficacy 
and safety of Primapur® and 










Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 
Intervention model: Parallel 
Assignment 
Masking: Single (Outcomes Assessor) 
Enrolment: 118 participants 
(20–35 years) 
Drugs: Primapur®, Gonal- F® 
• Number of oocytes (Intention-to-
Treat, ITT) [primary] 
• Number of follicles with size ≥16 
mm 
• Number of metaphase II (MII) 
oocytes 
• Number of fertilised oocytes 
• Percentage of patients with 
Embryo Transfer 
• Total FSH dose administered 
• Days of stimulation 
• Number of patients with FSH 
dose correction 
• Number of patients with cycle 
cancellation 
• Number of no-responders 
• Pregnancy rate 
• Clinical pregnancy rate 
DA-3801® NCT01820728 
A Phase III clinical study to 
compare the efficac and 










Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 
Intervention model: Parallel 
Assignment 
Masking: None (Open Label) 
Enrollment: 93 participants 
(20–38 years) 
Drugs: DA-3801, Gonal-F® 
• Ovulation rate after 3 cycles 
[primary] 
• Total FSH dose administered 
• Days of stimulation 
• Threshold dose, IU 
• Number of follicles 
FOLITIME® NCT02454556 
A randomized, multicentre, 
open label, evaluator 
blinded study to evaluate 
safety and efficacy of 
Folitime® of Gemabiotech 
S.A. versus Gonal-F® of 
Merck Serono, in patients 









Study Type: Interventional 
Phase: Phase III 
Allocation: Randomized 
Intervention model: Parallel 
Assignment 
Masking: Single (Outcomes Assessor) 
Enrollment: 106 participants 
(18–37 years) 
Drugs: FOLITIME®, Gonal-F® 
• Number of retrieved [primary] 
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Table 1. Cont. 
LM-001® NCT03535103 
Study on the safety and 
pharmacokinetics of LM001 








Study Type: Interventional 
Phase: Phase I 
Allocation: Randomized 
Intervention model: Crossover 
Assignment 
Masking: None (Open Label) 
Enrollment: 32 participants 
(18–40 years) 
Drugs: LM001, Gonal-F®  
• Maximum observed serum 
concentration (Cmax) of LM001 & 
Gonal-F® [primary] 
• Adjusted geometric means of area 
under the serum concentration-time 
curve from time zero to the time of 
last quantifiable concentration 
(AUC(0-T)) for LM001 & Gonal-F® 
[primary] 
• Time of Maxmum observed 













Study Type: Interventional 
Phase: Phase 4 
Allocation: N/A 
Intervention model: Single Group 
Assignment 
Masking: None (Open Label) 





• Number of retrieved oocytes 
[primary] 
• Number of metaphase II (MII) 
oocytes [primary] 
• Oocyte quality 
• Eventual AE/SAEs related to the 
administration of Gonapure® 
• Total and mean Gonapure ® dose 
administered 
• Number of follicles ≥18 mm at the 
ovulation trigger  
• Multiple pregnancy rate 
• OHSS rate 
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7. Cost-Effectiveness Evaluation of Follitropin α Biosimilars vs. Originator in the European 
Context 
A cost-effectiveness evaluation comparing the originator follitropin α Gonal-F® to the biosimilar 
Bemfola®, based on data derived from the registration study by Rettenbacher [65], established that 
the originator r-hFSH is more cost-efficient than the biosimilar relative to the conditions of medical 
reimbursement existing in Italian and Spanish health systems. All clinical data and the costs of the 
procedure, including the overall r-hFSH dose and the costs related to drugs, hospitalizations and 
examinations were taken into account and related to the number of live births; compared to the 
originator, the biosimilar generated an higher cost of € 3600 for Italy and € 900 for Spain [70]. 
In the French context with National Health Service perspective, the average increased cost per 
live birth was € 259.56 and € 278.39, respectively, for Ovaleap® and Bemfola® vs. Gonal-F® that 
resulted to be cost-effective compared to its biosimilars [71]. 
Moreover, the cost-effectiveness of Gonal-F® in comparison to Bemfola® and Ovaleap® from a 
German payer perspective was reported. Results indicated that the average cost per live birth for 
women treated with the originator was lower: Bemfola® and Ovaleap® were associated with a higher 
cost of € 4168 and € 7540, respectively, per additional live birth [72]. 
Concerning the cost/effectiveness of biosimilar FSH preparations, further studies are needed, 
extending the investigation also to other countries with different systems of public health economy 
where biosimilars are on the market. 
8. Conclusions 
Interestingly enough, the worldwide web-based survey [73], showed that most IVF Centers 
(67.3%) are aware of the availability of FSH biosimilars on the market, but 90% of them require more 
complete information on these products. This limits the clinical use of biosimilars, as a relatively low 
number of centres (25.6%) reported to have clinical experience with these new products. 
As a matter of fact, the two follitropin α biosimilars already authorized and marketed as 
Ovaleap® and Bemfola® were compared to the reference product Gonal-F® in a few studies performed 
on selected, good prognosis patients, and powered to detect a difference in the number of retrieved 
oocytes. The most important endpoints of IVF, the live birth rate and the incidence of OHSS, were 
considered just secondary endpoints and the inadequate number of observations did not allow 
reaching any meaningful conclusion about the equivalence of the biosimilars to the originator with 
their respect. 
Moreover, the canonical Gs/cAMP/protein kinase A pathway, considered for a long time as the 
sole effector of the hFSH receptor-mediated signaling, is now viewed just as one of several 
mechanisms employed by hFSH receptor to transduce intracellular signals in response to the 
stimulus [74]. The complexity of the hFSH receptor-mediated intracellular signals activated in 
response to ligand binding allows for a fine-tuning regulation of the gonadotropic stimulus, where 
activation/inhibition of its multiple components vary depending on the cell context, cell 
developmental stage, concentration of associated receptors and, above all, corresponding ligands. 
For this reason, and in light of the different glycosylation profiles of biosimilars, linked to source 
and/or purification process [13,66], other signaling pathways may be involved in determining r-hFSH 
action and potentially may cause subtle differences in the final outcome after clinical use of r-hFSH 
medications. 
Post marketing, real-world data studies and pharmacovigilance data are definitely needed to 
assess whether follitropin α biosimilars really have comparable clinical efficacy to the originator, 
expanding observation also to “non-ideal” patients and reaching a much higher number of 
observations. To date, despite promising data, there is no proof yet of the equivalence of r-hFSH 
biosimilars with their originator in the real-life patient population undergoing IVF and with respect 
to the only endpoint that really matters, which is live birth rate and OHSS incidence. Definitely, 
further well designed and properly powered trials are needed in this area. 
Pharmaceuticals 2020, 13, 136 20 of 23 
 
Author Contributions: A.R.; methodology, L.B and S.C.; validation, L.B., S.C., G.G. and A.R..; data curation, 
L.B., and S.C.; writing—original draft preparation, L.B and S.C.; writing—review and editing, L.B., S.C., A R.C., 
C.P., G.G., F.S., C.B and A.R..; visualization, A.R.C. and C.P.; supervision, C.B. and A.R..; All authors have read 
and agreed to the published version of the manuscript. 
Funding: This research received no external funding. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1.  Daya, S. Follicle-stimulating hormone in clinical practice: an update. Treat. Endocrinol. 2004, 3, 161–171, 
doi:10.2165/00024677-200403030-00004. 
2.  Santi, D.; Potì, F.; Simoni, M.; Casarini, L. Pharmacogenetics of G-protein-coupled receptors variants: FSH 
receptor and infertility treatment. Best Pract. Res. Clin. Endocrinol. Metab. 2018, 32, 189–200, 
doi:10.1016/j.beem.2018.01.001. 
3.  Leão, R. de B.F.; Esteves, S.C. Gonadotropin therapy in assisted reproduction: an evolutionary perspective 
from biologics to biotech. Clinics 2014, 69, 279–293, doi:10.6061/clinics/2014(04)10. 
4.  Cai, Q.; Wan, F.; Huang, K.; Zhang, H. Does the Number of Oocytes Retrieved Influence Pregnancy after 
Fresh Embryo Transfer? PLoS ONE 2013, 8, doi:10.1371/journal.pone.0056189. 
5.  Sunkara, S.K.; Rittenberg, V.; Raine-Fenning, N.; Bhattacharya, S.; Zamora, J.; Coomarasamy, A. 
Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment 
cycles. Hum. Reprod. Oxf. Engl. 2011, 26, 1768–1774, doi:10.1093/humrep/der106. 
6.  Butnev, V.Y.; Butnev, V.Y.; May, J.V.; Shuai, B.; Tran, P.; White, W.K.; Brown, A.; Smalter Hall, A.; Harvey, 
D.J.; Bousfield, G.R. Production, purification, and characterization of recombinant hFSH glycoforms for 
functional studies. Mol. Cell. Endocrinol. 2015, 405, 42–51, doi:10.1016/j.mce.2015.01.026. 
7.  Olijve, W.; de Boer, W.; Mulders, J.W.; van Wezenbeek, P.M. Molecular biology and biochemistry of human 
recombinant follicle stimulating hormone (Puregon). Mol. Hum. Reprod. 1996, 2, 371–382, 
doi:10.1093/molehr/2.5.371. 
8.  Morell, A.G.; Gregoriadis, G.; Scheinberg, I.H.; Hickman, J.; Ashwell, G. The role of sialic acid in 
determining the survival of glycoproteins in the circulation. J. Biol. Chem. 1971, 246, 1461–1467. 
9.  Andersen, C.Y.; Westergaard, L.G.; van Wely, M. FSH isoform composition of commercial gonadotrophin 
preparations: a neglected aspect? Reprod. Biomed. Online 2004, 9, 231–236, doi:10.1016/s1472-6483(10)62135-
9. 
10.  Lombardi, A.; Andreozzi, C.; Pavone, V.; Triglione, V.; Angiolini, L.; Caccia, P. Evaluation of the 
oligosaccharide composition of commercial follicle stimulating hormone preparations. Electrophoresis 2013, 
34, 2394–2406, doi:10.1002/elps.201300045. 
11.  Bousfield, G.R.; Butnev, V.Y.; Rueda-Santos, M.A.; Brown, A.; Hall, A.S.; Harvey, D.J. Macro- and Micro-
heterogeneity in Pituitary and Urinary Follicle-Stimulating Hormone Glycosylation. J. Glycomics Lipidomics 
2014, 4, doi:10.4172/2153-0637.1000125. 
12.  Jiang, C.; Hou, X.; Wang, C.; May, J.V.; Butnev, V.Y.; Bousfield, G.R.; Davis, J.S. Hypoglycosylated hFSH 
Has Greater Bioactivity Than Fully Glycosylated Recombinant hFSH in Human Granulosa Cells. J. Clin. 
Endocrinol. Metab. 2015, 100, E852–E860, doi:10.1210/jc.2015-1317. 
13.  Riccetti, L.; Sperduti, S.; Lazzaretti, C.; Klett, D.; De Pascali, F.; Paradiso, E.; Limoncella, S.; Potì, F.; 
Tagliavini, S.; Trenti, T.; et al. Glycosylation Pattern and in vitro Bioactivity of Reference Follitropin alfa 
and Biosimilars. Front. Endocrinol. 2019, 10, 503, doi:10.3389/fendo.2019.00503. 
14.  Bousfield, G.R.; May, J.V.; Davis, J.S.; Dias, J.A.; Kumar, T.R. In Vivo and In Vitro Impact of Carbohydrate 
Variation on Human Follicle-Stimulating Hormone Function. Front. Endocrinol. 2018, 9, 
doi:10.3389/fendo.2018.00216. 
15.  Bassett, R.M.; Driebergen, R. Continued improvements in the quality and consistency of follitropin alfa, 
recombinant human FSH. Reprod. Biomed. Online 2005, 10, 169–177, doi:10.1016/s1472-6483(10)60937-6. 
16.  Revelli, A.; Pettinau, G.; Basso, G.; Carosso, A.; Ferrero, A.; Dallan, C.; Canosa, S.; Gennarelli, G.; Guidetti, 
D.; Filippini, C.; et al. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. 
human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical 
practice in a real-life population. Reprod. Biol. Endocrinol. RBE 2015, 13, 77, doi:10.1186/s12958-015-0080-6. 
Pharmaceuticals 2020, 13, 136 21 of 23 
 
17.  Daya, S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for 
ovarian stimulation in assisted reproduction. Fertil. Steril. 2002, 77, 711–714, doi:10.1016/s0015-
0282(01)03246-0. 
18.  Keene, J.L.; Matzuk, M.M.; Otani, T.; Fauser, B.C.; Galway, A.B.; Hsueh, A.J.; Boime, I. Expression of 
biologically active human follitropin in Chinese hamster ovary cells. J. Biol. Chem. 1989, 264, 4769–4775. 
19.  Hugues, J.N.; Durnerin, I.C. Gonadotrophins--filled-by-mass versus filled-by-bioassay. Reprod. Biomed. 
Online 2005, 10 Suppl 3, 11–17, doi:10.1016/s1472-6483(11)60385-4. 
20.  GONAL-f. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f (accessed on 
21 May 2020). 
21.  Puregon Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/puregon (accessed on 
21 May 2020). 
22.  Follistim AQ (follitropin beta) FDA Approval History. Available online: 
https://www.drugs.com/history/follistim-aq.html (accessed on 21 May 2020). 
23.  Rekovelle | European Medicines Agency. Available online: 
https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle (accessed on 16 May 2020). 
24.  Goa, K.L.; Wagstaff, A.J. Follitropin alpha in infertility: a review. BioDrugs Clin. Immunother. Biopharm. Gene 
Ther. 1998, 9, 235–260, doi:10.2165/00063030-199809030-00006. 
25.  Olsson, H.; Sandström, R.; Grundemar, L. Different pharmacokinetic and pharmacodynamic properties of 
recombinant follicle-stimulating hormone (rFSH) derived from a human cell line compared with rFSH from 
a non-human cell line. J. Clin. Pharmacol. 2014, 54, 1299–1307, doi:10.1002/jcph.328. 
26.  Koechling, W.; Plaksin, D.; Croston, G.E.; Jeppesen, J.V.; Macklon, K.T.; Andersen, C.Y. Endocr. Connect. 
2017, 6, 297–305, doi:10.1530/EC-17-0067. 
27.  Mochtar, M.H.; Danhof, N.A.; Ayeleke, R.O.; Van der Veen, F.; van Wely, M. Recombinant luteinizing 
hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI 
cycles. Cochrane Database Syst. Rev. 2017, 5, CD005070, doi:10.1002/14651858.CD005070.pub3. 
28.  Bordewijk, E.M.; Mol, F.; van der Veen, F.; Van Wely, M. Required amount of rFSH, HP-hMG and HP-FSH 
to reach a live birth: a systematic review and meta-analysis. Hum. Reprod. Open 2019, 2019, hoz008, 
doi:10.1093/hropen/hoz008. 
29.  Mignini Renzini, M.; Brigante, C.; Coticchio, G.; Dal Canto, M.; Caliari, I.; Comi, R.; De Ponti, E.; Fadini, R. 
Retrospective analysis of treatments with recombinant FSH and recombinant LH versus human 
menopausal gonadotropin in women with reduced ovarian reserve. J. Assist. Reprod. Genet. 2017, 34, 1645–
1651, doi:10.1007/s10815-017-1034-z. 
30.  Weiss, N.S.; Nahuis, M.; Bayram, N.; Mol, B.W.J.; Van der Veen, F.; van Wely, M. Gonadotrophins for 
ovulation induction in women with polycystic ovarian syndrome. Cochrane Database Syst. Rev. 2015, 
CD010290, doi:10.1002/14651858.CD010290.pub2. 
31.  Hugues, J.-N. Recombinant human follicle-stimulating hormone: a scientific step to clinical improvement. 
Reprod. Biomed. Online 2001, 2, 54–64, doi:10.1016/S1472-6483(10)62188-8. 
32.  Rekovelle. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/rekovelle (accessed 
on 17 May 2020). 
33.  Administration, A.G.D. of H.T.G. Search the TGA website. Available online://www.tga.gov.au/search/node 
(accessed on 21 May 2020). 
34.  Lunenfeld, B.; Bilger, W.; Longobardi, S.; Alam, V.; D’Hooghe, T.; Sunkara, S.K. The Development of 
Gonadotropins for Clinical Use in the Treatment of Infertility. Front. Endocrinol. 2019, 10, 
doi:10.3389/fendo.2019.00429. 
35.  Cole, L.A. hCG, the wonder of today’s science. Reprod. Biol. Endocrinol. RBE 2012, 10, 24, doi:10.1186/1477-
7827-10-24. 
36.  Sacchi, S.; Tenedini, E.; Tondelli, D.; Parenti, S.; Tagliasacchi, D.; Xella, S.; Marsella, T.; Tagliafico, E.; Marca, 
A.L. Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin 
alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH). Gynecol. Endocrinol. 2019, 35, 623–
627, doi:10.1080/09513590.2019.1576611. 
37.  Abd-Elaziz, K.; Duijkers, I.; Stöckl, L.; Dietrich, B.; Klipping, C.; Eckert, K.; Goletz, S. A new fully human 
recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled 
pharmacokinetic and pharmacodynamic trials. Hum. Reprod. Oxf. Engl. 2017, 32, 1639–1647, 
doi:10.1093/humrep/dex220. 
Pharmaceuticals 2020, 13, 136 22 of 23 
 
38.  Griesinger, G.; Dietrich, B.; Stöckl, L.; Eckert, K.; Goletz, S.; Tandler-Schneider, A. Fully human glyco-
optimized recombinant FSH (follitropin epsilon) – a randomized, comparator-controlled phase II clinical 
trial. Reprod. Biomed. Online 2020, 40, 331–341, doi:10.1016/j.rbmo.2019.09.003. 
39.  Harlin, J.; Csemiczky, G.; Wramsby, H.; Fried, G. Recombinant follicle stimulating hormone in in-vitro 
fertilization treatment-clinical experience with follitropin alpha and follitropin beta. Hum. Reprod. Oxf. Engl. 
2000, 15, 239–244, doi:10.1093/humrep/15.2.239. 
40.  Brinsden, P.; Akagbosu, F.; Gibbons, L.M.; Lancaster, S.; Gourdon, D.; Engrand, P.; Loumaye, E. A 
comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone 
preparations in patients undergoing in vitro fertilization-embryo transfer. Fertil. Steril. 2000, 73, 114–116, 
doi:10.1016/s0015-0282(99)00450-1. 
41.  Nyboe Andersen, A.; Nelson, S.M.; Fauser, B.C.J.M.; García-Velasco, J.A.; Klein, B.M.; Arce, J.-C.; ESTHER-
1 study group Individualized versus conventional ovarian stimulation for in vitro fertilization: a 
multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil. Steril. 2017, 107, 
387-396.e4, doi:10.1016/j.fertnstert.2016.10.033. 
42.  Beligotti, F. Commentary: The Development of Gonadotropins for Clinical Use in the Treatment of 
Infertility. Front. Endocrinol. 2020, 11, 151, doi:10.3389/fendo.2020.00151. 
43.  Fernández-Sánchez, M.; Visnova, H.; Yuzpe, A.; Klein, B.M.; Mannaerts, B.; Arce, J.-C.; ESTHER-1 and 
ESTHER-2 Study Group Individualization of the starting dose of follitropin delta reduces the overall OHSS 
risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. 
Reprod. Biomed. Online 2019, 38, 528–537, doi:10.1016/j.rbmo.2018.12.032. 
44.  Bosch, E.; Havelock, J.; Martin, F.S.; Rasmussen, B.B.; Klein, B.M.; Mannaerts, B.; Arce, J.-C.; ESTHER-2 
Study Group Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 
safety trial. Reprod. Biomed. Online 2019, 38, 195–205, doi:10.1016/j.rbmo.2018.10.012. 
45.  Out, H.J.; Mannaerts, B.M.; Driessen, S.G.; Bennink, H.J. A prospective, randomized, assessor-blind, 
multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus 
Metrodin) in in-vitro fertilization. Hum. Reprod. Oxf. Engl. 1995, 10, 2534–2540, 
doi:10.1093/oxfordjournals.humrep.a135740. 
46.  Revelli, A.; Pittatore, G.; Casano, S.; Canosa, S.; Evangelista, F.; Benedetto, C. Efficacy and safety of late-
start Corifollitropin-alfa administration for controlled ovarian hyperstimulation in IVF: a cohort, case-
control study. J. Assist. Reprod. Genet. 2015, 32, 429–434, doi:10.1007/s10815-014-0426-6. 
47.  Revelli, A.; Gennarelli, G.; Sestero, M.; Canosa, S.; Carosso, A.; Salvagno, F.; Pittatore, G.; Filippini, C.; 
Benedetto, C. A prospective randomized trial comparing corifollitropin-α late-start (day 4) versus standard 
administration (day 2) in expected poor, normal, and high responders undergoing controlled ovarian 
stimulation for IVF. J. Assist. Reprod. Genet. 2020, 37, 1163–1170, doi:10.1007/s10815-020-01742-5. 
48.  Weise, M.; Bielsky, M.-C.; De Smet, K.; Ehmann, F.; Ekman, N.; Narayanan, G.; Heim, H.-K.; Heinonen, E.; 
Ho, K.; Thorpe, R.; et al. Biosimilars-why terminology matters. Nat. Biotechnol. 2011, 29, 690–693, 
doi:10.1038/nbt.1936. 
49.  Research, C. for D.E. and Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. 
Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-
considerations-demonstrating-biosimilarity-reference-product (accessed on 5 May 2020). 
50.  Kuhlmann, M.; Covic, A. The protein science of biosimilars. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. 
Transpl. Assoc. - Eur. Ren. Assoc. 2006, 21 Suppl 5, v4-8, doi:10.1093/ndt/gfl474. 
51.  Mellstedt, H.; Niederwieser, D.; Ludwig, H. The challenge of biosimilars. Ann. Oncol. Off. J. Eur. Soc. Med. 
Oncol. 2008, 19, 411–419, doi:10.1093/annonc/mdm345. 
52.  Schiestl, M.; Stangler, T.; Torella, C.; Cepeljnik, T.; Toll, H.; Grau, R. Acceptable changes in quality attributes 
of glycosylated biopharmaceuticals. Nat. Biotechnol. 2011, 29, 310–312, doi:10.1038/nbt.1839. 
53.  de Mora, F.; Fauser, B.C.J.M. Biosimilars to recombinant human FSH medicines: comparable efficacy and 
safety to the original biologic. Reprod. Biomed. Online 2017, 35, 81–86, doi:10.1016/j.rbmo.2017.03.020. 
54.  Santi, D.; Simoni, M. Biosimilar recombinant follicle stimulating hormones in infertility treatment. Expert 
Opin. Biol. Ther. 2014, 14, 1399–1409, doi:10.1517/14712598.2014.925872. 
55.  Winstel, R.; Wieland, J.; Gertz, B.; Mueller, A.; Allgaier, H. Manufacturing of Recombinant Human Follicle-
Stimulating Hormone Ovaleap® (XM17), Comparability with Gonal-f®, and Performance/Consistency. 
Drugs RD 2017, 17, 305–312, doi:10.1007/s40268-017-0182-z. 
Pharmaceuticals 2020, 13, 136 23 of 23 
 
56.  Anonymous Bemfola. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/bemfola 
(accessed on 9 May 2020). 
57.  Announcements Richter acquires all Bemfola® rights in respect of US. Available online: 
https://www.richter.hu/en-US/investors/announcements/Pages/extraord180710.aspx (accessed on 26 May 
2020). 
58.  Gloaguen, P.; Crépieux, P.; Heitzler, D.; Poupon, A.; Reiter, E. Mapping the Follicle-Stimulating Hormone-
Induced Signaling Networks. Front. Endocrinol. 2011, 2, doi:10.3389/fendo.2011.00045. 
59.  Ayoub, M.A.; Landomiel, F.; Gallay, N.; Jégot, G.; Poupon, A.; Crépieux, P.; Reiter, E. Assessing 
Gonadotropin Receptor Function by Resonance Energy Transfer-Based Assays. Front. Endocrinol. 2015, 6, 
130, doi:10.3389/fendo.2015.00130. 
60.  Jonas, K.C.; Chen, S.; Virta, M.; Mora, J.; Franks, S.; Huhtaniemi, I.; Hanyaloglu, A.C. Temporal 
reprogramming of calcium signalling via crosstalk of gonadotrophin receptors that associate as 
functionally asymmetric heteromers. Sci. Rep. 2018, 8, 2239, doi:10.1038/s41598-018-20722-5. 
61.  Orvieto, R.; Seifer, D.B. Biosimilar FSH preparations- are they identical twins or just siblings? Reprod. Biol. 
Endocrinol. RBE 2016, 14, doi:10.1186/s12958-016-0167-8. 
62.  Ovaleap. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/ovaleap (accessed on 
17 May 2020). 
63.  Strowitzki, T.; Kuczynski, W.; Mueller, A.; Bias, P. Randomized, active-controlled, comparative phase 3 
efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in 
infertile women using assisted reproduction technology (ART). Reprod. Biol. Endocrinol. RBE 2016, 14, 1, 
doi:10.1186/s12958-015-0135-8. 
64.  Wolzt, M.; Gouya, G.; Sator, M.; Hemetsberger, T.; Irps, C.; Rettenbacher, M.; Vcelar, B. Comparison of 
pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. Eur. 
J. Drug Metab. Pharmacokinet. 2016, 41, 259–265, doi:10.1007/s13318-015-0257-6. 
65.  Rettenbacher, M.; Andersen, A.N.; Garcia-Velasco, J.A.; Sator, M.; Barri, P.; Lindenberg, S.; van der Ven, K.; 
Khalaf, Y.; Bentin-Ley, U.; Obruca, A.; et al. A multi-centre phase 3 study comparing efficacy and safety of 
Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod. Biomed. Online 
2015, 30, 504–513, doi:10.1016/j.rbmo.2015.01.005. 
66.  Mastrangeli, R.; Satwekar, A.; Cutillo, F.; Ciampolillo, C.; Palinsky, W.; Longobardi, S. In-vivo biological 
activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone 
product (Bemfola) compared with its reference medicinal product (GONAL-f). PloS One 2017, 12, e0184139, 
doi:10.1371/journal.pone.0184139. 
67.  Biosimilar Versus Urinary Gonadotropins - Full Text View - ClinicalTrials.gov. Available online: 
https://clinicaltrials.gov/ct2/show/NCT02503605 (accessed on 17 May 2020). 
68.  Barakhoeva, Z.; Vovk, L.; Fetisova, Y.; Marilova, N.; Ovchinnikova, M.; Tischenko, M.; Scherbatyuk, Y.; 
Kolotovkina, A.; Miskun, A.; Kasyanova, G.; et al. A multicenter, randomized, phase III study comparing 
the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur. J. Obstet. Gynecol. 
Reprod. Biol. 2019, 241, 6–12, doi:10.1016/j.ejogrb.2019.07.032. 
69.  Moon, S.Y.; Choi, Y.S.; Ku, S.-Y.; Kim, S.H.; Choi, Y.M.; Kang, I.S.; Kim, C.H. Comparison of the efficacy 
and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha 
(Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. 
J. Obstet. Gynaecol. Res. 2007, 33, 305–315, doi:10.1111/j.1447-0756.2007.00529.x. 
70.  Gizzo, S.; Garcia-Velasco, J.A.; Heiman, F.; Ripellino, C.; Bühler, K. A cost-effectiveness evaluation 
comparing originator follitropin alfa to the biosimilar for the treatment of infertility. Int. J. Womens Health 
2016, 8, 683–689, doi:10.2147/IJWH.S118687. 
71.  Grynberg, M.; Murphy, C.; Doré, C.; Fresneau, L.; Paillet, S.; Petrica, N.; Frédérique, M.; Ravonimbola, H. 
A cost-effectiveness analysis comparing the originator follitropin alfa to its biosimilars in patients 
undergoing a medically assisted reproduction program from a French perspective. J. Med. Econ. 2018, 1–15, 
doi:10.1080/13696998.2018.1551226. 
72.  Xue, W.; Lloyd, A.; Falla, E.; Roeder, C.; Papsch, R.; Bühler, K. A cost-effectiveness evaluation of the 
originator follitropin alpha compared to the biosimilars for assisted reproduction in Germany. Int. J. 
Womens Health 2019, 11, 319–331, doi:10.2147/IJWH.S193048. 
Pharmaceuticals 2020, 13, 136 24 of 23 
 
73.  Christianson, M.S.; Shoham, G.; Tobler, K.J.; Zhao, Y.; Monseur, B.; Leong, M.; Shoham, Z. Use of various 
gonadotropin and biosimilar formulations for in vitro fertilization cycles: results of a worldwide Web-
based survey. J. Assist. Reprod. Genet. 2017, 34, 1059–1066, doi:10.1007/s10815-017-0952-0. 
74.  Ulloa-Aguirre, A.; Reiter, E.; Crépieux, P. FSH Receptor Signaling: Complexity of Interactions and Signal 
Diversity. Endocrinology 2018, 159, 3020–3035, doi:10.1210/en.2018-00452. 
 
 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
 
